Get the Stockscreener App
24.88
2.26%
+0.55
After Hours:
25.05
0.17
+0.68%
BridgeBio Pharma Inc stock is currently priced at $24.88, with a 24-hour trading volume of 1.04M.
It has seen a +2.26% increased in the last 24 hours and a -16.40% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $24.17 pivot point. If it approaches the $25.00 resistance level, significant changes may occur.
Previous Close:
$24.33
Open:
$24.48
24h Volume:
1.04M
Market Cap:
$4.66B
Revenue:
$9.30M
Net Income/Loss:
$-643.20M
P/E Ratio:
-6.3795
EPS:
-3.9
Net Cash Flow:
$-529.03M
1W Performance:
+0.57%
1M Performance:
-16.40%
6M Performance:
-0.76%
1Y Performance:
+74.11%
1D Range:
$24.32
$24.99
52W Range:
$12.75
$44.32
BridgeBio Pharma Inc Stock (BBIO) Company Profile
Name
BridgeBio Pharma Inc
Sector
Industry
Phone
650-391-9740
Address
421 Kipling Street, Palo Alto, CA
BridgeBio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
BridgeBio Pharma Inc Stock (BBIO) Latest News
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GlobeNewswire Inc.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Zacks Investment Research
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
BridgeBio Pharma Inc Stock (BBIO) Financials Data
BridgeBio Pharma Inc (BBIO) Revenue 2024
BBIO reported a revenue (TTM) of $9.30 million for the quarter ending December 31, 2023, a -88.02% decline year-over-year.
BridgeBio Pharma Inc (BBIO) Net Income 2024
BBIO net income (TTM) was -$643.20 million for the quarter ending December 31, 2023, a -33.67% decrease year-over-year.
BridgeBio Pharma Inc (BBIO) Cash Flow 2024
BBIO recorded a free cash flow (TTM) of -$529.03 million for the quarter ending December 31, 2023, a -24.24% decrease year-over-year.
BridgeBio Pharma Inc (BBIO) Earnings per Share 2024
BBIO earnings per share (TTM) was -$3.94 for the quarter ending December 31, 2023, a -20.49% decline year-over-year.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.
1.53%
3.38%
Cap:
|
Volume (24h):